Request Demo
Novartis gains global rights to Legend’s CAR-T cell therapies in deal worth over $1bn
ImmunotherapyLicense out/inCell TherapyAcquisitionClinical Study
Novartis has entered into an exclusive licence agreement with Legend Biotech for global rights to a selection of CAR-T cell therapies targeting DLL3, with the deal potentially worth over $1bn.
Novartise terms of the agreement, Novartis will gain exclusiveLegend Biotechhts to develop, manufacture and commercialise these cell therapies, DLL3h include an autologous CAR-T cell therapy candidate (LB2102) that Legend is taking into early-stage clinical development for extensive stage small cell lung cancer and large cell neuroendocrine carcinoma.
The deal also allows Novartis to aNovartis T-Charge cell therapy platform to the manufacturing process of these therapies, with LB2102 set to be the company's first application of T-Charge to a cell theLB2102andidate targeting solid tumours.small cell lung cancerlarge cell neuroendocrine carcinoma
In exchange, Legend wNovartisive a $100m upfront payment from Novartis and will be eligible to receive up to $1.01bn in clinicalLB2102latory and commercial milestone payments and tiered royalties.solid tumours
“We believe LB2102 has an innovative CAR design and armour mecNovartishat increases its anti-tumour activity,” said Guowei Fang, chief scientific officer and head of business development at Legend Biotech. “The preclinical evidence shows that an autologous CAR-T could be a differentiated treatment option for patients with small cell lung cancer.”
Fang added tLB2102e combination of LB2102 with Novartis’ T-Charge platform “may potentially otumourransformative benefits to small cell lung cancer patients”.Legend BiotechCAR-Tsmall cell lung cancer
The Novartis/Legend agreement is juLB2102 of a Novartisf deals that Novartis has made this year. In July, the company announcsmall cell lung cancerDTx Pharma, a preclinical stage biotech focused on developing siRNA therapies for neuroscience indications, in a transaction worth up to $1bn.
The Novartisncluded DTx’s fatty acid ligand-conjugated oligonucleotiNovartisorm as well as its lead preclinical therapy for Charcot-Marie-Tooth disDTx Pharmaow-progressing and degenerative disease of the peripheral nervous system.
The month prior, theDTxDTxiss drugmaker also entered into an agreement to acquire Chinook Therapeutics for approximately $3.5bnCharcot-Marie-Tooth diseaseon of its renal pipeline.degenerative disease of the peripheral nervous system
The deal granted Novartis access to the US biopharma’s two late-stage candidateChinook Therapeutics immunoglobulin A nephropathy, a rare and progressive kidney disease that mostly affects young adults.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.